Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fortress Biotech

1.71
+0.01000.59%
Post-market: 1.710.00000.00%19:58 EDT
Volume:131.07K
Turnover:222.56K
Market Cap:47.20M
PE:-0.50
High:1.74
Open:1.68
Low:1.66
Close:1.70
Loading ...

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease

PR Newswire
·
06 Jan

BUZZ-Checkpoint Therapeutics rises after FDA approval of co's skin cancer drug

Reuters
·
16 Dec 2024

BRIEF-Checkpoint Therapeutics Announces FDA Approval Of Unloxcyt (Cosibelimab-Ipdl)

Reuters
·
14 Dec 2024

Fortress Biotech price target lowered to $4 from $5 at Alliance Global Partners

TIPRANKS
·
18 Nov 2024

Fortress Biotech price target raised to $26 from $24 at H.C. Wainwright

TIPRANKS
·
18 Nov 2024

Fortress Biotech Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
17 Nov 2024

Fortress Biotech Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
15 Nov 2024

Fortress Biotech Q3 EPS $(0.76) Beats $(1.15) Estimate, Sales $14.63M Miss $32.22M Estimate

Benzinga
·
15 Nov 2024

Fortress Biotech: Q3 Earnings Snapshot

Associated Press Finance
·
15 Nov 2024

Fortress Biotech Inc : Qtrly Shr Loss $0.76

THOMSON REUTERS
·
15 Nov 2024

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

GlobeNewswire
·
15 Nov 2024

Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

THOMSON REUTERS
·
15 Nov 2024

Avenue Therapeutics Inc: Qtrly Shr Loss $1.92

THOMSON REUTERS
·
15 Nov 2024

Fortress Biotech Inc expected to post a loss of 59 cents a share - Earnings Preview

Reuters
·
13 Nov 2024

Checkpoint Therapeutics Inc Qtrly Shr Loss $0.23

THOMSON REUTERS
·
13 Nov 2024

Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

THOMSON REUTERS
·
13 Nov 2024